The DOI matches its OpenAlex record.
Prenatal Dexamethasone Treatment in Conjunction with Rescue Therapy of Human Surfactant: A Randomized Placebo-Controlled Multicenter Study
Abstract
OBJECTIVES: A placebo-controlled, randomized, double-blind study was performed to determine whether prenatal dexamethasone (DEX) treatment improves the outcome of the preterm infant when exogenous surfactant is available. METHODS: 157 pregnant women at five hospitals with threatened preterm delivery and with lengths of gestation < 32 weeks received either DEX (dose 6 mg four times at 12-hour intervals) or placebo (PL). Prenatal treatment was not repeated. Preterm infants received rescue therapy of human surfactant (maximum four doses) if they required ventilatory support and at least 40% oxygen for the treatment of respiratory distress syndrome (RDS). RESULTS: Enrolled pregnant women delivered 188 live-born neonates, of whom 79 (DEX 41 and PL 38 neonates) were born 1 to 14 days after the prenatal treatment. Neonates born within 1 to 14 days after the initial DEX treatment had a lower incidence of RDS (DEX, 44%; PL, 79%; P < .01), lower requirements of surfactant (DEX, 22%; PL, 53%; P < .01), shorter duration of ventilatory support (DEX, 2.0 days; PL, 5.3 days; P < .05) and oxygen therapy (DEX, 2.0 days; PL, 7.0 days; P < .01), and a higher neonatal survival without ventilatory support (P < .05) than PL-treated neonates. DEX-treated neonates had higher mean blood pressure than PL-treated neonates during the first 3 days after birth. Among all neonates treated with DEX, there was a lower incidence of intraventricular hemorrhage or periventricular leucomalacia (DEX, 13%; PL, 33%; P < .01). Reduction in the incidence of intraventricular hemorrhage or periventricular leucomalacia in DEX-treated neonates was particularly associated with exogenous human surfactant therapy (DEX+surfactant 10%; PL+surfactant 48%; P < .01). CONCLUSIONS: Prenatal DEX treatment combined with exogenous human surfactant therapy in preterm infants decreases pulmonary morbidity and cerebral complications, and increases survival without severe morbidity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth
Roberts, D., Brown, J., Medley, N., & Dalziel, S. R. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004454.pub3 · Cited by 2,806
Antenatal corticosteroid therapy: A meta-analysis of the randomized trials, 1972 to 1994
Crowley, P. A. (1995) · American Journal of Obstetrics and Gynecology · doi:10.1016/0002-9378(95)90222-8 · Cited by 880
Prenatal glucocorticoids and long-term programming
Seckl (2004) · European Journal of Endocrinology · doi:10.1530/eje.0.151u049 · Cited by 825
“Moreover, at least a proportion of these physiological systems are also glucocorticoid sensitive in early life, since cortisol also elevates foetal blood pressure when infused directly in utero in sheep (42) and at birth in sheep (43) and humans (44).”
BackgroundAntenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth
McGoldrick, E., Stewart, F., Parker, R., & Dalziel, S. R. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004454.pub4 · Cited by 614
SECKL, J. R., & MEANEY, M. J. (2004) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1314.006 · Cited by 556
Prophylactic corticosteroids for preterm birth
Crowley, P. (1996) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000065 · Cited by 505
RetractedInterventions for Perinatal Hypoxic–Ischemic Encephalopathy
Vannucci, R. C., & Perlman, J. M. (1997) · Pediatrics · doi:10.1542/peds.100.6.1004 · Cited by 464
Surfactant Replacement Therapy for Preterm and Term Neonates With Respiratory Distress
Polin, R. A., Carlo, W. A., COMMITTEE ON FETUS AND NEWBORN, Papile, L.-A., Polin, R. A., Carlo, W., Tan, R., Kumar, P., Benitz, W., Eichenwald, E., et al. (2014) · Pediatrics · doi:10.1542/peds.2013-3443 · Cited by 413
Glucocorticoid programming of the fetus; adult phenotypes and molecular mechanisms
Seckl, J. R. (2001) · Molecular and Cellular Endocrinology · doi:10.1016/s0303-7207(01)00633-5 · Cited by 392
Surfactant-Replacement Therapy for Respiratory Distress in the Preterm and Term Neonate
Engle, W. A., & and the Committee on Fetus and Newborn (2008) · Pediatrics · doi:10.1542/peds.2007-3283 · Cited by 308
The Pulmonary Surfactant System: Biochemical and Clinical Aspects
Creuwels, L. A. J. M., van Golde, L. M. G., & Haagsman, H. P. (1997) · Lung · doi:10.1007/pl00007554 · Cited by 304
Seckl, J. R. (1997) · Steroids · doi:10.1016/s0039-128x(96)00165-1 · Cited by 298
Glucocorticoid “Programming” and PTSD Risk
SECKL, J. R., & MEANEY, M. J. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1364.027 · Cited by 234
Braun, T., Challis, J. R., Newnham, J. P., & Sloboda, D. M. (2013) · Endocrine Reviews · doi:10.1210/er.2013-1012 · Cited by 196
Metadata
- Authors
- Kari, M. A., Eronen, M., Virtanen, M., Hallman, M., Teramo, K., Koivisto, M., & Ikonen, R.
- Venue
- PEDIATRICS
- Publisher
- American Academy of Pediatrics
- Published
- 1994-05-01
- Volume
- 93
- Issue
- 5
- Pages
- 730-736
- ISSN
- 0031-4005 (ISSN-L)
- OpenAlex
- W122014714
- Cited by
- 271
- References
- 0
- FWCI
- 17.81
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.